|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Retevmo
gptkb:Genzyme_Genetics
|
|
gptkbp:activities
|
inhibitor of ALK and MET tyrosine kinases
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:2011
gptkb:Australia
gptkb:FDA
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:clinical_trial
|
Phase 3 trials
maintenance therapy
Phase 1 trials
Phase 2 trials
second-line treatment
first-line treatment
|
|
gptkbp:contraindication
|
hypersensitivity to crizotinib
|
|
gptkbp:developed_by
|
gptkb:Pfizer
|
|
gptkbp:dosage_form
|
250 mg twice daily
|
|
gptkbp:formulation
|
film-coated tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Crizotinib
|
|
gptkbp:ingredients
|
C21 H22 Cl2 N4 O2 S
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
|
|
gptkbp:lifespan
|
42 hours
|
|
gptkbp:marketed_as
|
gptkb:Xalkori
gptkb:2011
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:population
|
ALK-positive NSCLC patients
MET-positive NSCLC patients
|
|
gptkbp:research_focus
|
oncology
personalized medicine
targeted therapy
|
|
gptkbp:safety_features
|
electrocardiograms
liver function tests
vision tests
complete blood counts
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
vomiting
diarrhea
liver enzyme elevation
thrombocytopenia
vision disorders
neutropenia
pneumonitis
bradycardia
QT prolongation
|
|
gptkbp:targets
|
gptkb:ALK_gene_rearrangements
MET gene alterations
|
|
gptkbp:type_of
|
877399-52-5
|
|
gptkbp:year_created
|
gptkb:2007
|